Thirona Raises €7.5 Million in New Financing

Thirona has secured €7.5 million ($8 million) in financing through a €5 million investment round from HERAN Partners and Borski Fund, and a €2.5 million grant from European Innovation Council (EIC). 

“We are very pleased with the confidence our investors have shown in our vision and capabilities,” Thirona Founder/CEO Eva van Rikxoort said. “This funding will enable us to continue pushing the boundaries of AI-powered imaging and help advance personalized treatment for lung patients around the world.”

With this financing, Thirona plans to accelerate the adoption of its precision medicine innovations. 

Thirona aims to revolutionize medical treatment and intervention pathways for lung diseases through cutting-edge artificial intelligence technologies. The company’s advanced capabilities in pre-operative and intra-operative imaging can potentially enhance the precision, accuracy, and efficiency of (robotic) bronchoscopic and surgical lung interventions, enabling easier-to-perform and less invasive procedures. Demonstrating consistently high performance across a wide range of diseases and pathologies, Thirona’s LungQ platform powers also a growing number of imaging-based exploratory research studies and clinical trials for development of novel pharmaceutical drugs. Having surpassed a total number of 15 million images analyzed, the company evolved to a technologically mature, globally recognized expert in advaced image analysis.
 
“Thirona has demonstrated exceptional promise in the field of medical imaging. We are excited to support their mission to revolutionize healthcare through AI technology,” stated Katleen Vandersmissen from HERAN Partners.

Simone Brummelhuis from Borski Found noted the latest investment will provide the company with the resources to expand its market presence. “Thirona has achieved major growth milestones, forged co-innovation partnerships with leading medical companies, and became leader in the medtech space for lung image analysis,” Brummelhuis said. 
 
“The future of healthcare is undergoing a transformation, and we are at the forefront of this evolution, leading the way in our field. With the support of the investors, we are well geared to have our technology make a significant impact on patient care and the medical industry,” Thirona Chief Technology Officer Rita Priori concluded.

Thirona is a global company providing high-precision advanced lung image analysis with artificial intelligence through expertise-based services for medtech, pharmaceutical, and CRO companies. Thirona partners with research institutions and medical companies in their innovation programs aimed to enable breakthroughs in precision medicine for personalized treatment of pulmonary diseases. Since its inception in 2014, the company has established a proven track record in translating technology into certified clinical end-products through co-innovation with medtech companies.